Lewy Body & Parkinson Dementia
Lewy Body & Parkinson Dementia
What Do You Need to Know?
- DLB core features: fluctuating cognition, recurrent well-formed visual hallucinations, REM sleep behavior disorder (RBD), spontaneous parkinsonism
- 1-year rule: dementia within 1 year of parkinsonism = DLB; dementia ≥1 year after established parkinsonism = PDD — same α-synuclein Lewy body pathology on a spectrum
- Neuroleptic sensitivity: even atypical antipsychotics can cause severe/fatal reactions; if absolutely needed → quetiapine (lowest risk) or pimavanserin (FDA-approved for PD psychosis)
- Indicative biomarkers: reduced dopamine transporter uptake (DaTscan), abnormal 123I-MIBG cardiac scintigraphy, PSG-confirmed RBD without atonia
- Cognitive profile: attention, executive function, and visuospatial domains disproportionately impaired early; memory relatively preserved (vs. AD)
- Treatment: rivastigmine (strongest evidence among cholinesterase inhibitors); melatonin first-line for RBD; cautious carbidopa-levodopa for motor symptoms
- Imaging: relative preservation of medial temporal lobe/hippocampus (vs. AD); occipital hypometabolism on FDG-PET; "cingulate island sign"
DLB Diagnostic Criteria (McKeith 2017)
Core Clinical Features
- Fluctuating cognition — pronounced variations in attention and alertness; may mimic delirium; spontaneous "good days and bad days"
- Recurrent visual hallucinations — well-formed, detailed (people, animals, children); often have insight early in course
- REM sleep behavior disorder (RBD) — dream enactment behavior; loss of normal REM atonia; may precede cognitive decline by decades
- Spontaneous parkinsonism — bradykinesia, rigidity, rest tremor; NOT drug-induced; often symmetric or mild early on
Diagnostic Certainty
| Diagnosis | Criteria |
|---|---|
| Probable DLB | ≥2 core features; OR 1 core feature + ≥1 indicative biomarker |
| Possible DLB | 1 core feature without indicative biomarker; OR ≥1 indicative biomarker alone (no core features) |
Indicative Biomarkers
| Biomarker | What It Shows | Board-Relevant Details |
|---|---|---|
| DaTscan (Ioflupane SPECT) | Reduced dopamine transporter uptake in basal ganglia | Abnormal in DLB, PD, MSA, PSP; normal in AD — key differentiator |
| 123I-MIBG cardiac scintigraphy | Reduced cardiac sympathetic innervation | Abnormal in DLB and PD (cardiac sympathetic denervation); normal in AD, MSA |
| PSG-confirmed RBD | REM sleep without atonia on polysomnography | RBD converts to α-synucleinopathy (DLB/PD/MSA) in >80% over 10–15 years |
Supportive Clinical Features
- Severe neuroleptic sensitivity — exaggerated extrapyramidal response to antipsychotics; can be fatal
- Postural instability and repeated falls
- Syncope or other transient episodes of unresponsiveness
- Severe autonomic dysfunction (orthostatic hypotension, urinary incontinence, constipation)
- Hypersomnia
- Hyposmia (reduced sense of smell)
- Systematized delusions (often paranoid/persecutory)
- Hallucinations in other modalities (auditory, tactile)
- Apathy, anxiety, depression
Supportive Biomarkers
- Relative preservation of medial temporal lobe on CT/MRI (vs. prominent hippocampal atrophy in AD)
- Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity
- Prominent posterior slow-wave activity on EEG with periodic fluctuations in the pre-alpha/theta range
- Insular thinning on MRI
💎 Board Pearl
- Probable DLB requires ≥2 core features OR 1 core + 1 indicative biomarker — biomarkers can "upgrade" a single core feature to probable
- DLB should NOT be diagnosed if parkinsonism is the only core feature and DaTscan is the only biomarker (both reflect same dopaminergic loss)
- RBD is the most specific predictor of future α-synucleinopathy — if present with cognitive decline, DLB is the leading differential
DLB vs. PDD vs. AD — The Key Comparisons
The 1-Year Rule
- DLB: dementia develops before or within 1 year of onset of parkinsonism
- PDD: dementia develops ≥1 year after well-established parkinsonism (usually many years into PD course)
- Both are α-synucleinopathies with cortical Lewy bodies — considered the same pathological spectrum
- The 1-year rule is a clinical convenience, not a biological boundary
Master Comparison Table: DLB vs. PDD vs. AD
| Feature | DLB | PDD | AD |
|---|---|---|---|
| Pathology | Cortical Lewy bodies (α-synuclein); often concomitant AD pathology | Cortical Lewy bodies (α-synuclein) | Amyloid plaques + neurofibrillary tangles (tau) |
| Timing | Dementia before or within 1 yr of parkinsonism | Dementia ≥1 yr after established parkinsonism | No parkinsonism at onset |
| Motor features | Spontaneous parkinsonism; often symmetric, less tremor-dominant | Preceded by typical PD motor features (asymmetric rest tremor) | Parkinsonism uncommon; if present, usually late and mild |
| Visual hallucinations | Early, prominent, well-formed | Common, usually later in PD course | Uncommon until late stages |
| Cognitive profile | Attention/executive/visuospatial worst; memory relatively preserved | Similar to DLB: executive/visuospatial | Episodic memory impairment earliest and most prominent |
| Fluctuations | Marked, prominent | Present but less prominent | Absent or minimal |
| RBD | Very common (core feature) | Very common | Uncommon |
| Neuroleptic sensitivity | Severe (hallmark) | Present | Not a typical feature |
| DaTscan | Abnormal | Abnormal | Normal |
| MIBG cardiac | Abnormal (reduced uptake) | Abnormal | Normal |
| MRI | Medial temporal lobe relatively preserved | Variable hippocampal atrophy | Early hippocampal/medial temporal atrophy |
| FDG-PET | Occipital hypometabolism; cingulate island sign | Similar to DLB | Temporoparietal hypometabolism; no cingulate island sign |
| Cholinesterase inhibitors | Effective (rivastigmine preferred) | Effective (rivastigmine FDA-approved) | Effective (donepezil most commonly used) |
| Levodopa response | Variable; less robust than PD | Initial response good (they have PD); may wane | Not applicable |
💎 Board Pearl
- The 1-year rule is the single most tested distinction between DLB and PDD: dementia within 1 year of motor onset = DLB; dementia ≥1 year after = PDD
- DaTscan abnormal + preserved medial temporal lobes + visual hallucinations = classic board-question DLB presentation (vs. AD)
- Concomitant AD pathology (amyloid plaques) is common in DLB and is associated with faster cognitive decline and less motor parkinsonism
Pathology
Lewy Body Formation
- Lewy bodies: intracytoplasmic, eosinophilic, spherical inclusions with a dense hyaline core and pale halo
- Composed primarily of misfolded α-synuclein + ubiquitin, neurofilament
- Lewy neurites: α-synuclein-positive dystrophic neurites; more numerous than Lewy bodies and likely more pathologically significant
- Brainstem Lewy bodies (substantia nigra, locus coeruleus) → motor parkinsonism
- Cortical Lewy bodies (limbic → neocortical) → cognitive impairment, hallucinations
Distribution Patterns
| Pattern | Distribution | Clinical Correlate |
|---|---|---|
| Brainstem-predominant | Substantia nigra, locus coeruleus, dorsal raphe, dorsal motor nucleus of vagus | Classical PD without dementia |
| Limbic (transitional) | Brainstem + amygdala, cingulate gyrus, transentorhinal cortex | PD with mild cognitive impairment; early DLB |
| Neocortical (diffuse) | Brainstem + limbic + frontal, temporal, parietal cortices | DLB or PDD with prominent dementia |
Concomitant AD Pathology in DLB
- ~50% of DLB cases have concurrent AD pathology (amyloid plaques ± neurofibrillary tangles)
- Higher amyloid burden in DLB correlates with: less parkinsonism, fewer fluctuations, more memory-predominant pattern, faster decline
- Pure Lewy body pathology (without AD copathology) → more classic DLB phenotype with prominent fluctuations and visual hallucinations
- Mixed AD + Lewy body pathology is one of the most common neuropathological findings at autopsy in elderly with dementia
💎 Board Pearl
- α-synuclein is the protein that forms Lewy bodies; tau forms neurofibrillary tangles (AD, PSP, CBD); TDP-43 is the hallmark of FTLD and ALS
- Braak PD staging tracks α-synuclein spread: olfactory bulb/dorsal motor nucleus → locus coeruleus → substantia nigra → mesocortex → neocortex
- Mixed AD + Lewy body pathology is the most common autopsy finding in patients clinically diagnosed with "AD" who also had visual hallucinations
Cognitive Profile
Cognitive Domains in DLB/PDD vs. AD
| Domain | DLB / PDD | AD |
|---|---|---|
| Attention | Severely impaired early; marked fluctuations | Relatively preserved early |
| Executive function | Disproportionately impaired (planning, set-shifting, judgment) | Impaired but less prominent than memory |
| Visuospatial | Severely impaired (clock drawing, figure copy, visual construction) | Impaired later; less severe |
| Episodic memory | Relatively preserved early; retrieval deficit (improves with cues) | Earliest and most impaired; encoding deficit (does NOT improve with cues) |
| Language | Generally preserved early | Word-finding difficulty early; semantic errors |
| Processing speed | Markedly slowed | Slowed but less pronounced |
Fluctuating Cognition
- Hallmark of DLB; described as spontaneous alterations in cognition, attention, and arousal
- May manifest as: staring spells, episodes of incoherent speech, excessive daytime somnolence alternating with lucid intervals
- Can mimic delirium — always consider DLB when an elderly patient has "delirium" without clear precipitant
- Clinician Assessment of Fluctuation (CAF) and One Day Fluctuation Assessment Scale — validated tools
- Fluctuations are more prominent in DLB than PDD
Clinical Pearl
- A patient with "delirium" that waxes and wanes over weeks without identifiable cause + well-formed visual hallucinations should raise suspicion for DLB, not just a metabolic workup
- DLB patients perform worse on clock drawing and figure copy than AD patients at the same stage of overall dementia severity — visuospatial testing is a key differentiator
Visual Hallucinations
Characteristics in DLB
- Well-formed and detailed — people (often children or strangers), animals, objects
- Typically visual; may be accompanied by auditory hallucinations but visual predominate
- Often occur in low-light conditions or at transitions between wakefulness and sleep
- Patient may have full or partial insight early in course (knows hallucinations are not real)
- Recurrent and stereotyped (similar content over time)
- Associated with cholinergic deficit in visual cortex and reduced occipital metabolism
Differential Diagnosis of Visual Hallucinations
| Condition | Hallucination Type | Distinguishing Features |
|---|---|---|
| DLB | Well-formed people/animals; recurrent | Associated parkinsonism, fluctuations, RBD; insight often preserved early |
| Charles Bonnet syndrome | Well-formed, complex visual imagery | Occurs with visual loss (macular degeneration, cataracts); no cognitive decline; full insight; no parkinsonism |
| Delirium | Poorly formed, often frightening | Acute onset; identifiable precipitant (infection, metabolic, medication); resolves with treatment |
| PD psychosis | Well-formed; often passage/presence hallucinations early | Occurs in context of long-standing PD; often medication-related (dopamine agonists > levodopa) |
| Peduncular hallucinosis | Vivid, well-formed, often at night | Midbrain/thalamic lesion; often have insight; associated with sleep disturbance |
| Epileptic (occipital seizures) | Elementary visual phenomena (flashes, colors); rarely formed | Brief, stereotyped, may have associated eye deviation |
💎 Board Pearl
- Well-formed visual hallucinations in an elderly patient with fluctuating cognition = DLB until proven otherwise
- Charles Bonnet syndrome is the main mimic — distinguished by visual loss, intact cognition, and absence of parkinsonism/RBD
- In PD, hallucinations often begin as minor phenomena (passage hallucinations — something moving in peripheral vision; presence hallucinations — feeling someone is nearby) before progressing to well-formed visual hallucinations
Neuroimaging
Structural MRI
- Relative preservation of medial temporal lobe and hippocampus — key distinction from AD
- Global cortical atrophy may be present but less specific
- Posterior cortical atrophy (parieto-occipital) may be seen
- MRI mainly useful to exclude other causes and to demonstrate absence of typical AD pattern
Functional and Molecular Imaging
| Modality | DLB Finding | AD Finding | Clinical Utility |
|---|---|---|---|
| FDG-PET | Occipital hypometabolism; relative preservation of posterior cingulate ("cingulate island sign") | Temporoparietal hypometabolism; posterior cingulate affected early | Cingulate island sign helps distinguish DLB from AD |
| DaTscan (SPECT) | Reduced striatal dopamine transporter uptake | Normal | Indicative biomarker for DLB; differentiates from AD |
| MIBG cardiac | Reduced heart-to-mediastinum ratio | Normal | Indicative biomarker; reflects cardiac sympathetic denervation |
| Amyloid PET | Positive in ~50% (concomitant AD pathology) | Positive (>90%) | Does NOT differentiate DLB from AD (both can be positive) |
| Perfusion SPECT | Reduced occipital perfusion | Reduced temporoparietal perfusion | Supportive biomarker for DLB |
💎 Board Pearl
- Cingulate island sign: relative preservation of posterior cingulate metabolism on FDG-PET in DLB (vs. early posterior cingulate hypometabolism in AD) — high specificity for Lewy body pathology
- DaTscan differentiates DLB from AD (abnormal in DLB, normal in AD) but does NOT distinguish DLB from MSA, PSP, or CBD
- Amyloid PET is NOT useful for DLB vs. AD differentiation — ~50% of DLB patients are amyloid-positive
Neuroleptic Sensitivity
Why It Matters
- Up to 50% of DLB patients have severe neuroleptic sensitivity reactions
- Reactions include: severe worsening of parkinsonism, impaired consciousness, rigidity, autonomic instability
- Can be fatal — resembles neuroleptic malignant syndrome (NMS)
- Mechanism: severe loss of nigrostriatal dopaminergic neurons + post-synaptic D2 receptor blockade → catastrophic dopamine depletion
- Occurs with typical antipsychotics (haloperidol, chlorpromazine) AND can occur with atypical antipsychotics (risperidone, olanzapine)
Management of Psychosis in DLB
Step 1: Non-pharmacologic and Medication Review
- Reduce or eliminate anticholinergics, benzodiazepines, dopamine agonists (taper before levodopa)
- Environmental modifications (adequate lighting, reduce sensory overload)
- Optimize cholinesterase inhibitor dose (may reduce hallucinations)
Step 2: If Antipsychotic Absolutely Needed
| Agent | Notes | Board Relevance |
|---|---|---|
| Pimavanserin | Selective 5-HT2A inverse agonist; no dopamine receptor blockade | FDA-approved for PD psychosis; does NOT worsen motor function; takes 4–6 weeks for effect; QTc prolongation risk |
| Quetiapine | Atypical antipsychotic with low D2 affinity | Lowest risk of worsening parkinsonism among atypicals; commonly used off-label; evidence base is modest |
| Clozapine | Atypical antipsychotic; minimal D2 blockade | Effective but requires absolute neutrophil count monitoring (agranulocytosis risk 1–2%); rarely used due to monitoring burden |
💎 Board Pearl
- NEVER give haloperidol to a patient with DLB — this is a classic board question; can cause irreversible parkinsonism or death
- Risperidone and olanzapine are also dangerous in DLB despite being "atypical" — they have significant D2 blockade
- Pimavanserin is the only FDA-approved drug for PD psychosis — works via 5-HT2A inverse agonism without dopamine blockade
- Cholinesterase inhibitors (rivastigmine) can improve hallucinations in DLB — always optimize before adding an antipsychotic
Treatment
Cognitive Symptoms
| Agent | Class | Evidence & Notes |
|---|---|---|
| Rivastigmine | Cholinesterase inhibitor (AChE + BuChE) | Strongest evidence in DLB/PDD; FDA-approved for PDD; improves cognition, behavioral symptoms, and hallucinations; patch formulation reduces GI side effects |
| Donepezil | Cholinesterase inhibitor (AChE) | Also effective; large Japanese RCT (DADE) showed benefit in DLB; may worsen parkinsonism in some patients |
| Galantamine | Cholinesterase inhibitor + nicotinic allosteric modulator | Less studied in DLB; may have benefit |
| Memantine | NMDA receptor antagonist | Modest benefit; may be added to cholinesterase inhibitor; generally well-tolerated |
Motor Symptoms
- Carbidopa-levodopa: first-line for motor parkinsonism in DLB; start low, titrate slowly
- Response is often less robust than in idiopathic PD
- Risk of worsening hallucinations and psychosis — balance motor benefit vs. psychiatric side effects
- Avoid dopamine agonists (pramipexole, ropinirole) — higher risk of hallucinations, impulse control disorders, and confusion
- Avoid anticholinergics (trihexyphenidyl, benztropine) — worsen cognition and hallucinations
RBD Management
| Treatment | Details |
|---|---|
| Melatonin (3–12 mg at bedtime) | First-line; restores REM atonia; fewer side effects; may need high doses |
| Clonazepam (0.25–1 mg at bedtime) | Second-line; reduces injurious behaviors; risk of sedation, falls, worsened OSA; use cautiously in elderly/demented |
| Environmental safety | Remove sharp objects from bedside; pad bed rails; consider floor mattress; bed partner safety |
Other Symptoms
- Autonomic dysfunction: orthostatic hypotension (fludrocortisone, midodrine, droxidopa); constipation (fiber, osmotic laxatives); urinary symptoms (avoid anticholinergics)
- Depression: SSRIs preferred (sertraline, citalopram); avoid tricyclics (anticholinergic burden)
- Excessive daytime somnolence: modafinil may help; optimize nighttime sleep
Clinical Pearl
- Rivastigmine is the only cholinesterase inhibitor with FDA approval for PDD; it also has the strongest evidence base in DLB
- DLB has a greater cholinergic deficit than AD (more basal forebrain loss) — this explains the often dramatic response to cholinesterase inhibitors
- Always add carbidopa-levodopa slowly and at the lowest effective dose — if hallucinations worsen, reduce levodopa and optimize rivastigmine first
RBD as a Prodromal Marker
Key Concepts
- RBD (REM sleep behavior disorder): loss of normal REM atonia → dream enactment (punching, kicking, shouting, falling out of bed)
- Diagnosed by polysomnography showing REM sleep without atonia (RSWA) + history of dream enactment
- Idiopathic/isolated RBD (iRBD) is the strongest known prodromal marker for α-synucleinopathy
Phenoconversion Rates
| Timeframe | Conversion Rate to α-Synucleinopathy |
|---|---|
| 5 years | ~33% |
| 10 years | ~75% |
| 14+ years | >90% |
- Converts to: DLB (~50%), PD (~35%), MSA (~15%)
- Conversion to DLB is more common when RBD is accompanied by early cognitive changes
💎 Board Pearl
- Isolated RBD converts to an α-synucleinopathy in >90% of patients over long-term follow-up — it is the most specific prodromal biomarker
- If a question describes an elderly man who "acts out his dreams" and injures his bed partner, then years later develops visual hallucinations and parkinsonism → DLB
- Secondary RBD causes to exclude: medications (SSRIs, SNRIs, TCAs, beta-blockers), narcolepsy, brainstem lesions
Autonomic Dysfunction
Key Features
- Autonomic dysfunction is a supportive feature of DLB and very common in both DLB and PDD
- Reflects Lewy body deposition in autonomic ganglia, intermediolateral cell column, and brainstem autonomic nuclei
Autonomic Manifestations
| System | Manifestation | Management |
|---|---|---|
| Cardiovascular | Orthostatic hypotension, postprandial hypotension, supine hypertension | Midodrine, droxidopa, fludrocortisone; compression stockings; salt supplementation; elevate head of bed |
| Gastrointestinal | Constipation (often earliest autonomic symptom), gastroparesis, dysphagia | Fiber, polyethylene glycol; avoid anticholinergics |
| Urogenital | Urinary urgency/frequency, nocturia, erectile dysfunction | Mirabegron (beta-3 agonist) preferred over antimuscarinics; avoid oxybutynin (crosses BBB) |
| Thermoregulatory | Anhidrosis, heat intolerance | Environmental modifications |
💎 Board Pearl
- Early severe autonomic failure (≤5 years of parkinsonism onset) is a red flag for MSA, not PD — but moderate autonomic dysfunction is common and expected in DLB/PDD
- Droxidopa is FDA-approved for neurogenic orthostatic hypotension in PD/DLB/MSA — it is a norepinephrine prodrug
- MIBG cardiac scintigraphy is abnormal in DLB/PD but normal in MSA — this distinction can help differentiate on boards
Prognosis & Distinguishing Features Summary
Prognosis
- DLB median survival from diagnosis: 5–8 years (shorter than AD)
- DLB with concomitant AD pathology has the worst prognosis
- PDD develops in ~80% of PD patients who survive >20 years
- Rate of cognitive decline in DLB is faster than AD in most studies
- Visual hallucinations, fluctuations, and neuroleptic sensitivity may improve with cholinesterase inhibitors but parkinsonism is progressive
Quick-Hit Board Review Table
| Board Question Clue | Think… |
|---|---|
| Visual hallucinations + fluctuating cognition + parkinsonism | DLB |
| Long-standing PD patient develops dementia years later | PDD |
| Worsened parkinsonism after haloperidol | DLB with neuroleptic sensitivity |
| Preserved hippocampi + occipital hypometabolism on FDG-PET | DLB (cingulate island sign) |
| Abnormal DaTscan + normal in "AD" workup | DLB, not AD |
| Elderly man acting out dreams + later develops dementia | RBD → DLB |
| Dementia + parkinsonism + reduced MIBG uptake | DLB (cardiac sympathetic denervation) |
| Rivastigmine improves both cognition and hallucinations | DLB (cholinergic deficit) |
| Well-formed visual hallucinations + intact vision + no PD | Consider DLB (vs. Charles Bonnet if visual loss present) |
| Early severe orthostatic hypotension + poor levodopa response | MSA (not DLB) |
💎 Board Pearl
- DLB is the second most common neurodegenerative dementia after AD, accounting for 15–25% of dementia at autopsy
- DLB is frequently misdiagnosed as AD — always ask about visual hallucinations, fluctuations, RBD, and parkinsonism
- The combination of abnormal DaTscan + preserved medial temporal lobes + visual hallucinations + RBD is virtually diagnostic of DLB on boards
References
- McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
- Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689-1707.
- Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157-169.
- Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142(3):744-759.
- Graff-Radford J, Lesnick TG, Boeve BF, et al. Predicting survival in dementia with Lewy bodies with hippocampal volumetry. Mov Disord. 2016;31(7):989-994.
- Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533-540.
- Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351(24):2509-2518.
- Fujishiro H, Ferman TJ, Boeve BF, et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies. J Neuropathol Exp Neurol. 2008;67(7):649-656.
- Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
- Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683-1697.